Journal
EXPERT REVIEW OF VACCINES
Volume 9, Issue 1, Pages 23-27Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.09.135
Keywords
adjuvant; CTL response; resiquimod; Toll-like receptor
Categories
Ask authors/readers for more resources
The development of vaccines for cancer and infectious diseases that require the predominant induction of cell-mediated immunity, including effective cytotoxic T lymphocyte (CTL) responses, remains a challenge. Over the past few years, numerous studies have demonstrated that targeting of antigens to immune receptors expressed by dendritic cells (DCs), such as Toll-like receptors (TLRs), elicits potent CTL responses. Therefore, the design of new adjuvants has focused on TLR agonists that elicit maturation of DCs to effectively link the innate and adaptative immune responses. The paper under evaluation describes the topical use of resiquimod, a TLR7/8 agonist, to enhance cross-priming to subcutaneously administered ovalbumin. The results obtained demonstrated that topical resiquimod is a potent adjuvant for subcutaneous vaccines, inducing clinically relevant antigen-specific CTL responses, which protect against B16-ovalbumin tumor challenge in mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available